Protagonist Therapeutics, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; filed March 15, 2023. This is an annual Form 10-K, not a quarterly filing. Protagonist is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its principal programs are wholly owned rusfertide and Janssen-partnered JNJ-2113, supported by a constrained-peptide discovery platform.
Business Context and Pipeline
- Rusfertide: Injectable hepcidin mimetic in development primarily for polycythemia vera. Phase 3 VERIFY began in the first quarter of 2022, with enrollment completion expected in the fourth quarter of 2023. Phase 2 REVIVE and PACIFIC studies continued.
- JNJ-2113: Orally delivered IL-23 receptor antagonist developed with Janssen. The 255-patient Phase 2b FRONTIER1 psoriasis study was completed in December 2022. The filing reports positive topline results announced in March 2023, with Phase 3 advancement expected.
- PN-943: Phase 2 IDEAL ulcerative-colitis program was substantially deprioritized. The company intended to complete the long-term extension period but did not expect to dedicate further internal clinical-development or manufacturing resources to the program.
- The company had 105 full-time equivalent employees at December 31, 2022, including 82 in research and development.
Financial Results and Key Metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| License and collaboration revenue | $26.6 million | $27.4 million | Down 3% |
| Research and development expense | $126.2 million | $126.0 million | Approximately flat |
| General and administrative expense | $31.7 million | $27.2 million | Up 17% |
| Loss from operations | $131.4 million | $125.8 million | Higher loss |
| Interest income | $4.1 million | $0.4 million | Higher by $3.6 million |
| Net loss | $127.4 million | $125.6 million | Higher loss of $1.8 million |
| Net loss per share | $2.60 | $2.71 | Improved per share due primarily to a larger share base |
| Cash used in operating activities | $108.1 million | $107.9 million | Approximately flat |
| Cash, cash equivalents and marketable securities at year-end | $237.4 million | $326.9 million | Down $89.5 million |
Revenue consisted of license and collaboration revenue from Janssen; the company has never generated product-sales revenue. The Janssen performance obligation was completed as of June 30, 2022. Stock-based compensation was $24.2 million, compared with $16.4 million in 2021. The filing does not present a conventional gross margin because the company is pre-commercial and reports collaboration revenue rather than product sales.
At December 31, 2022, total assets were $247.9 million, total liabilities were $32.3 million, and stockholders’ equity was $215.6 million. The company had no outstanding debt; liabilities primarily consisted of operating lease obligations and ordinary-course payables. Accrued clinical and research expenses were $19.1 million.
Material Changes Versus the Prior Comparable Period
- Rusfertide clinical and development expense increased 17% to $64.8 million as the program advanced toward Phase 3.
- PN-943 expense declined modestly, while JNJ-2113 expense fell substantially because Janssen assumed primary responsibility for later-stage development.
- General and administrative expense increased 17%, driven by personnel-related and other business-support costs.
- Revenue declined slightly as Janssen-related performance obligations neared completion; the company recognized $26.6 million in 2022 and completed the initial collaboration performance obligation by midyear.
- Cash and marketable securities declined from $326.9 million to $237.4 million, reflecting continuing operating cash burn despite $18.8 million of financing cash inflows.
- The company sold 422,367 shares under its prior ATM facility for net proceeds of $14.6 million and established a new $100.0 million ATM facility in August 2022; no shares had been sold under the new facility by year-end.
Cash Runway, Outlook, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations and capital requirements for at least the next 12 months from the filing date, based on the current operating plan.
- Management expected 2023 cash burn and research and development expense to decrease near term because of PN-943 de-prioritization and streamlined discovery activities, although rusfertide development and pre-commercialization spending will continue.
- The company expects to require substantial additional funding to complete clinical development and pursue potential commercialization. Future financing could dilute shareholders or require debt, licensing or collaboration arrangements.
- Rusfertide’s FDA clinical hold related to tumors observed in a 26-week transgenic mouse carcinogenicity study was removed in October 2021, but additional cancer surveillance and safety controls remain important risks. The company voluntarily withdrew rusfertide’s Breakthrough Therapy designation in June 2022; Fast Track designation remains active.
- The company remains dependent on Janssen’s continued development of JNJ-2113. It is eligible for future development and sales milestones, including potential payments of $10 million, $50 million, $15 million and $115 million tied to specified Phase 2 and Phase 3 events, plus tiered royalties. These payments are contingent and are not assured.
- Key risks include clinical-trial failure or delay, patient-enrollment challenges, regulatory actions, adverse safety findings, reliance on contract research organizations and manufacturers, intellectual-property challenges, competition, reimbursement and pricing pressure, inflation, geopolitical disruption and ongoing capital-market volatility.
- The company reported no material pending legal proceedings. It has potential future obligations to Zealand Pharma of up to $2.75 million in rusfertide-related development milestones, in addition to amounts already paid under the arbitration resolution.
- Subsequent to year-end and through the filing date, the company sold 1,749,199 shares under the 2022 ATM facility for net proceeds of $24.3 million.
Most Important Facts for Investors to Verify
- Current enrollment status, timing and safety data for the rusfertide VERIFY Phase 3 trial.
- Full FRONTIER1 data for JNJ-2113, including response rates by dose, durability and detailed adverse-event results.
- Whether Janssen initiates Phase 3 development and the timing and probability of related milestone payments.
- Updated cash burn, cash runway and additional equity issuance under the ATM facility.
- Regulatory follow-up regarding rusfertide’s prior clinical hold, carcinogenicity findings and long-term cancer surveillance.
- The company’s ability to obtain approval, reimbursement and commercial manufacturing capacity for rusfertide, as no product is currently approved.